Explore the words cloud of the ADVANTAGE project. It provides you a very rough idea of what is the project "ADVANTAGE" about.
The following table provides information about the project.
|Coordinator Country||United Kingdom [UK]|
|Total cost||3˙893˙307 €|
|EC max contribution||3˙583˙396 € (92%)|
1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
|Duration (year-month-day)||from 2015-07-01 to 2018-06-30|
Take a look of project's partnership.
|1||PROTEINLOGIC LIMITED||UK (CAMBRIDGE CAMBRIDGESHIRE)||coordinator||2˙921˙750.00|
|2||BIOSENSIA LIMITED||IE (DUBLIN)||participant||661˙646.00|
Tuberculosis (TB) remains an EU and global healthcare priority resulting in over 1.4 million deaths each year. Despite this and efforts to reduce TB by the EU commission, the WHO and others, a simple, rapid, diagnostic test for active tuberculosis (TB) remains elusive. Current diagnostic procedures, while accounting for over $1 bn globally, are poorly selective for active TB, hold risks for healthcare personnel, are slow to yield results and costly.
The large potential and high unmet need provide a clear target for commercialisation of a point-of-care (POC) test. Using over 400 clinical samples, ProteinLogic (a UK based diagnostics company) have demonstrated proof of concept for a ground-breaking approach using a panel of protein biomarkers on human serum samples that profile the cell mediated patient response to TB.
The objectives of the eight structured work packages within this three year project are to build on the validation of the biomarker TB panel transitioning from a laboratory assay to Biosensia’s novel microfluidic POC platform that has already been successfully proven with a variety of human analytes. Reagents will be developed as part of this project to ensure reduced costs and security of commercial supply. A unique instrument reader plus TB cartridge-based product will be developed to meet EU regulatory standards. The products will be validated in order to confirm analytical and clinical performance, and to provide evidence of major time, cost & performance improvements compared to current TB testing practises. Successful commercialisation will lead to the creation of over 30 new jobs and will stimulate further private investment in each of the companies.
In summary, ADVANTAGE has the potential to deliver a disruptive POC TB diagnostic test that can help eradicate the massive TB burden not only in EU but also globally.
|Clone scale||Websites, patent fillings, videos etc.||2019-05-30 13:18:55|
Take a look to the deliverables list in detail: detailed list of ADVANTAGE deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADVANTAGE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ADVANTAGE" are provided by the European Opendata Portal: CORDIS opendata.
Preventing Respiratory Events through Proactive Assessment of Respiratory EffortRead More
ADvanced Validation of A Novel TB Active disease diagnostic to address Global unmet needs: a European consortium approachRead More
Development of a digital diagnostics rapid Lung Maturity Test (LMT) for premature infants, to assist neonatologists in the diagnosis of Respiratory Distress Syndrome at birthRead More